Clinical efficacy and safety of atomoxetine hydrochloride in the treatment of attention deficit hyperactivity disorder with transient tic disorder
10.13699/j.cnki.1001-6821.2016.08.002
- VernacularTitle:盐酸托莫西汀治疗儿童多动症合并短暂性抽动障碍的临床疗效及安全性评价
- Author:
Shuan-Feng FANG
1
;
Xiao-Hua ZHU
;
Bei YE
;
Jing CHEN
;
Hui-Li HE
Author Information
1. 郑州市儿童医院儿童保健科
- Keywords:
atomoxetine hydrochloride;
attention deficit hyperactivity disorder;
transient tic disorder;
clinical efficacy
- From:
The Chinese Journal of Clinical Pharmacology
2016;32(8):678-680
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of atomoxetine on attention deficit hyperactivity disorder ( ADHD ) children with transient tic disorder.Methods Sixty children of ADHD combined with transient tic disorder were randomly divided into control group ( n=30 ) and treatment group ( n=30 ) .Control group was treated with hydrochloric acid 10 mg, once a day.Treatment group was treated with atomoxetine hydrochloride 0.5 mg? kg-1 , qd, day 1-7, after 7 days, increase the dose to 1.2 mg? kg -1 , but the maximum dose should not exceed 1.4 mg? kg-1 . Two groups of children were treated for 2 months.The clinical efficacy, attention deficit ( AD) , hyperactivity im-pulse ( HI ) , ADHD score and the incidence of adverse drug reactions were compared between two groups.Results After treatment, the total effective rates of ADHD symptoms and transient tic disorder in treatment group were significantly higher than those of control group ( 83.33% vs 76.67%, 80.00%vs 53.33%, P<0.05 ) .After treatment, the AD, ADHD, HI scores of two groups were significantly lower than those before treatment, and the score of treatment group was significantly better than that of control group ( P <0.05 ) . The incidence of adverse drug reactions in the treatment group was slightly lower than that of control group without statistically significant difference (56.67%vs 60.00%, P>0.05).Conclusion Atomoxetine hydrochloride has a definitive clinical efficacy for the treatment of ADHD combined with transient tic disorder, without increasing of the incidence of adverse drug reactions.
